State of the
Count on Quest for tests supported by industry-leading expertise
Our co-testing solutions for cervical cancer are built on a strong combination of carefully evaluated Pap and high performing mRNA testing for high risk HPV.
Not all Pap tests are created equal
While we offer a choice of Pap collection systems, Quest Diagnostics recommends the ThinPrep® Pap test, due to its high clinical performance and specimen availability.
|higher high-grade lesions (HSIL) detection than conventional Pap testing1|
Studies have found that liquid-based cytology enhanced the co-testing detection of cervical cancer and CIN3/AIS to a greater extent than with conventional Pap smear and HPV co-testing.2
Industry-renowned laboratory quality
With our robust cervical cancer testing menu, rely on Pap testing from Quest Diagnostics to help you make a more informed diagnosis for your patients.
Aptima® HPV mRNA testing: excellent sensitivity and better specificity vs HPV DNA testing
The Aptima® HPV mRNA assay identifies the presence and activity of high-risk HPV infections, allowing you to identify and focus on those women who most need your care.
- More specificity,3 which can minimize false positives4 and reduce unnecessary invasive procedures
- Identifies HPV types most associated with cervical cancer, including adenocarcinoma, which has been increasing for decades3,5,6
|Aptima HPV has been shown to reduce false positives by 24% vs digene HC24|
mRNA and cervical disease8,9
Click here for more information about the Aptima HPV mRNA Assay.
Important information about the Aptima® HPV Assay
The Aptima HPV Assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (in ThinPrep® Pap Test vials containing PreservCyt® Solution and collected with broom-type or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See www.genprobe.com for more details.
The assay is not a substitute for regular cervical cytology screening. The results of this test are not intended to prevent women from proceeding to colposcopy. The assay has not been evaluated for managing HPV-vaccinated women, women with prior ablative or excisional therapy, hysterectomy, who are pregnant, or have other risk factors. Aptima and other associated logos are registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
This test is not intended for use in determining the need for treatment (i.e, excisional or ablative treatment of the cervix) in the absence of high-grade cervical intraepithelial neoplasia (CIN). Patients who are HPV 16, 18/45 positive should be monitored carefully for the development of high-grade CIN according to current practice guidelines. The Aptima HPV 16, 18/45 Genotype Assay is not intended for use as a stand-alone assay. The assay should be performed only as a follow-up to an Aptima HPV Assay positive result, and should be interpreted in conjunction with cervical cytology test results. The Aptima HPV 16, 18/45 Genotype Assay is not intended for use in women under age 30 with normal cervical cytology. The Aptima HPV 16, 18/45 Genotype Assay is not intended to substitute for regular cervical cytology screening. The use of this test has not been evaluated for the management of HPV vaccinated women, women with prior ablative or excisional therapy, hysterectomy, who are pregnant, or who have other risk factors (e.g., HIV+, immunocompromised, history of sexually transmitted infection).
- ThinPrep 2000 system [package insert]. MAN-02624-001 Rev.004. Marlborough, MA; Hologic, Inc.; 2017.
- Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150(5):385-392. doi: 10.1093/ajcp/aqy114
- Aptima HPV Assay (package insert) AW-10958 Rev., 002, 2015-02. San Diego, CA; Hologic, Inc.; 2017.
- Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691-701. doi: 10.1002/ijc.25726
- US Department of Health and Human Services. NIH fact sheets. Cervical cancer. https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76. Updated June 30, 2018. Accessed May 17, 2019.
- Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359. doi: 10.1002/ijc.27485
- Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913. doi: 10.1038/bjc.2013.22
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525-541. doi: 10.1042/CS20050369
- Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2536-2545. doi: 10.1158/1055-9965.EPI-08-0306